HRA Pharma And Maxwellia To Launch The UK’s First OTC Daily Contraceptives
Executive Summary
The UK's MHRA has approved the Rx-to-OTC switch of two identical progestogen-only contraceptive pills from HRA Pharma and Maxwellia. Hana and Lovima (both 75mcg desogestrel) will be launched at the end of the month.
You may also be interested in...
People On The Move: Appointments At Futura Medical, Bayer And Maxwellia
The latest appointments in Europe's consumer health industry: Former Perrigo exec Jeff Needham joins Futura Medical; Bayer promotes Gomez to lead Swiss Consumer business; and Maxwellia appoints Al-Attbi to newly-created role.
Private Label OTC Giant Stretches For Switch Help
HRA brings needed expertise in OTC switches to Perrigo, which regularly is first to launch generic equivalents for brand switches but its name hasn’t been linked to submitting proposals for making additional drug ingredients available OTC.
Perrigo Continues Overhaul Adding HRA Pharma, Boosts Chances For OTC Oral Contraceptive In US
HRA’s approval for pharmacy sales of a daily oral contraceptive the UK and its ongoing work on an NDA to propose making another progestin-only contraceptive ingredient available OTC in the US stand out as additions to Perrigo’s business with the most substantial revenue impacts.